Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy

Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients

(2019) Joshua P Lewis et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

(2019) Jean-Claude Tardif et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

(2018) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes

(2018) Daniel Lindholm et al.   JAMA Cardiology

Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome

(2017) Angela Lowenstern et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

(2017) William R. Hiatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

(2013) Robert F. Storey et al.   PLATELETS

Inflammation in Atherosclerosis

(2012) Peter Libby   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

(2012) Stefan M. Nidorf et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: Importance of metabolites

(2012) Swarna Maseneni et al.   TOXICOLOGY

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET

Clopidogrel pathway

(2010) Katrin Sangkuhl et al.   Pharmacogenetics and Genomics

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE